CO6630173A2 - Moléculas de unión a seroalbuminae - Google Patents
Moléculas de unión a seroalbuminaeInfo
- Publication number
- CO6630173A2 CO6630173A2 CO12197670A CO12197670A CO6630173A2 CO 6630173 A2 CO6630173 A2 CO 6630173A2 CO 12197670 A CO12197670 A CO 12197670A CO 12197670 A CO12197670 A CO 12197670A CO 6630173 A2 CO6630173 A2 CO 6630173A2
- Authority
- CO
- Colombia
- Prior art keywords
- present
- seroalbuminae
- binding molecules
- relates
- fibronectin
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102100037362 Fibronectin Human genes 0.000 abstract 1
- 102000002090 Fibronectin type III Human genes 0.000 abstract 1
- 108050009401 Fibronectin type III Proteins 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
Abstract
La presente invención se refiere a una proteína tipo anticuerpo que se basa en el dominio de fibronectina tipo III a la décima (Fn3) que se une a seroalbúmina, y la presente invención proporciona un polipéptido que comprende un dominio de fibronectina tipo III a la décima (Fn3). La presente invención también se refiere a moléculas de fusión que comprenden una (Fn3) de unión a seroalbúmina ligada a una proteína heteróloga para usar en aplicaciones terapéuticas y de diagnóstico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33067210P | 2010-05-03 | 2010-05-03 | |
US13/098,851 US8969289B2 (en) | 2010-05-03 | 2011-05-02 | Serum albumin binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6630173A2 true CO6630173A2 (es) | 2013-03-01 |
Family
ID=44628186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12197670A CO6630173A2 (es) | 2010-05-03 | 2012-11-01 | Moléculas de unión a seroalbuminae |
Country Status (21)
Country | Link |
---|---|
US (4) | US8969289B2 (es) |
EP (1) | EP2566888A2 (es) |
JP (3) | JP5876872B2 (es) |
KR (1) | KR101854931B1 (es) |
CN (2) | CN103003301B (es) |
AR (1) | AR081459A1 (es) |
AU (1) | AU2011248273B2 (es) |
BR (1) | BR112012028162A2 (es) |
CA (1) | CA2798510A1 (es) |
CL (1) | CL2012003077A1 (es) |
CO (1) | CO6630173A2 (es) |
EA (1) | EA029334B1 (es) |
IL (1) | IL222832A0 (es) |
MX (2) | MX346557B (es) |
PE (1) | PE20130593A1 (es) |
SG (2) | SG185091A1 (es) |
TN (1) | TN2012000518A1 (es) |
TW (1) | TW201138808A (es) |
UY (1) | UY33366A (es) |
WO (1) | WO2011140086A2 (es) |
ZA (1) | ZA201209091B (es) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
CN104163864B (zh) | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
MX2010008874A (es) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico. |
CN102099373A (zh) | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | 基于纤连蛋白的多价支架结构域蛋白 |
EP4074327A1 (en) * | 2008-06-27 | 2022-10-19 | Duke University | Therapeutic agents comprising elastin-like peptides |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
US9139629B2 (en) | 2010-06-05 | 2015-09-22 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
US9475850B2 (en) * | 2010-06-05 | 2016-10-25 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
US20130331329A1 (en) * | 2011-02-24 | 2013-12-12 | The Trustees Of The University Of Pennsylvania | Biomarkers for seizures |
WO2012122464A1 (en) * | 2011-03-10 | 2012-09-13 | New York University | Methods and compositions for modulating tnf/tnfr signaling |
DK2697257T3 (en) | 2011-04-13 | 2017-01-30 | Bristol Myers Squibb Co | FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS |
US9347058B2 (en) | 2011-05-17 | 2016-05-24 | Bristol-Myers Squibb Company | Methods for the selection of binding proteins |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
EP2729481B1 (en) * | 2011-07-08 | 2018-10-17 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
EP2773659A2 (en) | 2011-10-31 | 2014-09-10 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
EP2827882B1 (en) | 2012-02-21 | 2020-04-08 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
PE20150954A1 (es) | 2012-09-13 | 2015-06-20 | Bristol Myers Squibb Co | Proteinas del dominio de soporte basadas en fibronectina que se fijan a miostatina |
US8921307B2 (en) | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
WO2014100913A1 (en) * | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
WO2014120891A2 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
ES2689372T3 (es) | 2013-02-06 | 2018-11-13 | Bristol-Myers Squibb Company | Proteínas de dominio de fibronectina tipo III con solubilidad mejorada |
ES2645634T3 (es) | 2013-02-12 | 2017-12-07 | Bristol-Myers Squibb Company | Métodos de replegado de proteínas a elevado pH |
EP2968587A2 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
EP2970415B1 (en) * | 2013-03-14 | 2018-12-19 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
CN103333255A (zh) * | 2013-06-28 | 2013-10-02 | 复旦大学 | 一种长效hiv‐1膜融合抑制剂 |
UY35671A (es) | 2013-07-25 | 2015-02-27 | Novartis Ag | Bioconjugados de polipéptidos de apelina sintética |
SG11201600211XA (en) | 2013-07-25 | 2016-02-26 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
CN103550790B (zh) * | 2013-11-04 | 2016-01-27 | 上海交通大学医学院附属瑞金医院 | 骨膜蛋白抗体及其在药物制备中的应用 |
JP6483117B2 (ja) | 2013-11-20 | 2019-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Aplnrモジュレーター及びその使用 |
CN113150117A (zh) * | 2014-03-20 | 2021-07-23 | 百时美施贵宝公司 | 新的结合血清白蛋白的纤连蛋白iii型结构域 |
AR099856A1 (es) * | 2014-03-27 | 2016-08-24 | Genentech Inc | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado |
KR20240024362A (ko) | 2014-10-24 | 2024-02-23 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
CA2968357A1 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
MX2017006530A (es) | 2014-11-25 | 2017-08-10 | Bristol Myers Squibb Co | Nuevos peptidos que se unen al ligando-1 de muerte programada (pd-l1) para formacion de imagen. |
JP6701217B2 (ja) | 2014-11-25 | 2020-05-27 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 生物学的製剤の18f−放射性標識方法および組成物 |
CN104587457B (zh) * | 2015-01-13 | 2017-03-22 | 广东海大畜牧兽医研究院有限公司 | 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法 |
MA41580A (fr) | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
WO2016164608A1 (en) * | 2015-04-07 | 2016-10-13 | Alector Llc | Methods of screening for sortilin binding antagonists |
CR20170482A (es) * | 2015-04-24 | 2018-03-07 | Viiv Healthcare Uk No 5 Ltd | Polipéptidos dirigidos a la fusión de vih |
RU2734169C2 (ru) * | 2015-06-12 | 2020-10-13 | Маккэй Медикл Фаундэйшн Зе Пресбайтериэн Чёч Ин Тайвэнь Маккэй Мемориал Хоспитэл | Способ получения повышающей регуляции экспрессии PD-L1, полипептиды, конъюгат, слитый полипептид, композиция и комбинация для обеспечения повышающей регуляции экспрессии PD-L1 |
US11390656B2 (en) * | 2015-08-04 | 2022-07-19 | New York University | Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases |
US10766946B2 (en) | 2015-09-23 | 2020-09-08 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type III domains |
WO2017180988A2 (en) | 2016-04-15 | 2017-10-19 | Indiana University Research And Technology Corporation | Fgf21 c-terminal peptide optimization |
WO2017210302A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Pet imaging with pd-l1 binding polypeptides |
US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
KR102461666B1 (ko) | 2016-06-03 | 2022-11-01 | 얀센 바이오테크 인코포레이티드 | 혈청 알부민 결합 피브로넥틴 iii 형 도메인 |
CN106110325A (zh) * | 2016-06-08 | 2016-11-16 | 上海朗安生物技术有限公司 | 一种新型 glp‑1 受体激动剂的制备方法及其在神经退行性疾病治疗领域的应用 |
CN107693775A (zh) * | 2016-08-08 | 2018-02-16 | 中国人民解放军沈阳军区总医院 | Creg蛋白用于预防或治疗体重超重、肥胖及其相关疾病的医药用途 |
WO2018052828A1 (en) * | 2016-09-14 | 2018-03-22 | Janssen Biotech, Inc. | Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof |
US11248022B2 (en) | 2017-03-08 | 2022-02-15 | The Regents Of The University Of Michigan | Glypican-3 peptide reagents and methods |
EP3626734A4 (en) * | 2017-03-16 | 2020-12-02 | Shenzhen Institutes of Advanced Technology | POLYPEPTIDE FOR REGULATING ENERGY METABOLISM AND USES THEREOF |
WO2018165933A1 (zh) * | 2017-03-16 | 2018-09-20 | 深圳先进技术研究院 | 调节糖代谢的多肽及其用途 |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
AU2018301412A1 (en) * | 2017-07-11 | 2020-01-30 | Alexion Pharmaceuticals, Inc. | Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof |
CN109957006B (zh) * | 2017-12-22 | 2021-04-20 | 深圳先进技术研究院 | 一种代谢素多肽人工抗原以及抗体和应用 |
CN109957005B (zh) * | 2017-12-22 | 2021-04-20 | 深圳先进技术研究院 | 一种代谢素多肽人工抗原及其制备方法、抗体以及应用 |
JP2021529516A (ja) * | 2018-06-18 | 2021-11-04 | アンウィタ バイオサイエンシス, インク. | サイトカイン融合タンパク質及びその使用 |
WO2020085766A1 (ko) * | 2018-10-24 | 2020-04-30 | 한국과학기술원 | 인간 혈장 알부민에 특이적으로 결합하는 신규한 폴리펩티드 및 이의 용도 |
CA3097443A1 (en) * | 2018-11-12 | 2020-05-22 | I-Mab Biopharma Us Limited | Fusion proteins containing cd47 antibodies and cytokines |
CN109821012A (zh) * | 2019-04-08 | 2019-05-31 | 河南师范大学 | 一种用于治疗代谢疾病的药物组合物及其缓释微球制剂 |
TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
CN111965356B (zh) * | 2019-11-28 | 2023-09-08 | 上海荣盛生物药业股份有限公司 | 巯基还原组合物及荧光微球层析试纸和应用 |
CN113092772A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液黏连蛋白亚组sa-2及其多肽片段在过敏性疾病中的应用 |
CN111521812B (zh) * | 2019-12-25 | 2023-02-17 | 瑞博奥(广州)生物科技股份有限公司 | 视神经脊髓炎谱系疾病生物标记物组及其应用和蛋白芯片、试剂盒 |
CN115322794A (zh) | 2020-01-11 | 2022-11-11 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
CN112694526B (zh) * | 2020-05-27 | 2023-01-20 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白 |
CN115667291A (zh) * | 2020-05-27 | 2023-01-31 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白 |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
CN114075272B (zh) * | 2020-08-10 | 2023-09-22 | 杭州俊丰生物工程有限公司 | 一种人神经调节蛋白4的制备方法 |
CN111983241B (zh) * | 2020-09-04 | 2022-05-20 | 四川大学华西医院 | 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法 |
CN112321720A (zh) * | 2020-11-05 | 2021-02-05 | 无锡和邦生物科技有限公司 | 一种艾塞那肽人血清白蛋白融合蛋白的纯化方法 |
CN114848795B (zh) * | 2021-02-03 | 2023-04-14 | 四川大学 | RORa蛋白及其激动剂在制备抗衰老药物中的应用 |
CN112870336B (zh) * | 2021-02-24 | 2022-06-14 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白制剂 |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
CN117586423A (zh) * | 2021-07-14 | 2024-02-23 | 北京质肽生物医药科技有限公司 | 用于代谢病症的融合多肽 |
TW202332694A (zh) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | 血清半衰期延長之pd-l1結合多肽 |
EP4413038A1 (en) | 2021-10-07 | 2024-08-14 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
CN114288414A (zh) * | 2021-12-07 | 2022-04-08 | 深圳先进技术研究院 | 一种跨血脑屏障的多肽及其衍生物和应用 |
CN114306630A (zh) * | 2021-12-07 | 2022-04-12 | 深圳先进技术研究院 | 一种靶向脑瘤的多肽及其衍生物和应用 |
WO2023183932A2 (en) * | 2022-03-25 | 2023-09-28 | New York University | Monobodies binding to intercellular adhesion molecule 2 (icam-2) |
CN114432429A (zh) * | 2022-04-12 | 2022-05-06 | 中国人民解放军军事科学院军事医学研究院 | 一种预防或治疗骨关节炎的活性分子及其应用 |
WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
CN117645661A (zh) * | 2022-09-02 | 2024-03-05 | 北京志道生物科技有限公司 | 一种聚乙二醇修饰的il-21衍生物及其应用 |
WO2024051796A1 (en) * | 2022-09-09 | 2024-03-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Albumin binding proteins, fusion proteins and uses thereof |
CN115433776B (zh) * | 2022-09-30 | 2023-12-22 | 中国医学科学院阜外医院 | Ccn3在调控血管平滑肌细胞钙化中的应用 |
CN115724951B (zh) * | 2022-11-15 | 2023-10-03 | 怡道生物科技(苏州)有限公司 | 与11型hpv结合的抗体或其抗原结合片段及其应用 |
WO2024153195A1 (en) * | 2023-01-18 | 2024-07-25 | Beijing Ql Biopharmaceutical Co., Ltd. | Liquid pharmaceutical compositions of fusion polypeptides and methods of uses thereof |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US5770697A (en) | 1986-11-04 | 1998-06-23 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US5641648A (en) | 1986-11-04 | 1997-06-24 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
US5367052A (en) | 1987-04-27 | 1994-11-22 | Amylin Pharmaceuticals, Inc. | Amylin peptides |
US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
WO1992002536A1 (en) | 1990-08-02 | 1992-02-20 | The Regents Of The University Of Colorado | Systematic polypeptide evolution by reverse translation |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5773574A (en) | 1990-12-03 | 1998-06-30 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
US5235041A (en) | 1990-12-28 | 1993-08-10 | Protein Polymer Technologies, Inc. | Purification of structurally ordered recombinant protein polymers |
HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
US5792742A (en) | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
US5661007A (en) | 1991-06-25 | 1997-08-26 | Genetics Institute, Inc. | Bone morphogenetic protein-9 compositions |
US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
AU2313392A (en) | 1991-08-01 | 1993-03-02 | University Research Corporation | Systematic polypeptide evolution by reverse translation |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
WO1994017097A1 (en) | 1993-01-19 | 1994-08-04 | Regents Of The University Of Minnesota | Synthetic fibronectin fragments as inhibitors of retroviral infections |
AU685803B2 (en) | 1993-03-29 | 1998-01-29 | University Of Cincinnati, The | Analogs of peptide YY and uses thereof |
WO1995011922A1 (en) | 1993-10-29 | 1995-05-04 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5559000A (en) | 1995-01-18 | 1996-09-24 | The Scripps Research Institute | Encoded reaction cassette |
DE19646372C1 (de) | 1995-11-11 | 1997-06-19 | Evotec Biosystems Gmbh | Genotyp und Phänotyp koppelnde Verbindung |
GB9618960D0 (en) | 1996-09-11 | 1996-10-23 | Medical Science Sys Inc | Proteases |
US5922676A (en) | 1996-09-20 | 1999-07-13 | The Burnham Institute | Methods of inhibiting cancer by using superfibronectin |
DE69739163D1 (de) | 1996-10-17 | 2009-01-22 | Mitsubishi Chem Corp | Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen |
CN1238366C (zh) | 1997-01-21 | 2006-01-25 | 综合医院公司 | 利用rna-蛋白融合体筛选蛋白 |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US5830434A (en) | 1997-02-26 | 1998-11-03 | Medical University Of South Carolina Foundation For Research Development | Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide |
EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | SINGLE CHAIN PROTEINS FIXING ANTIGENS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF |
CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6159722A (en) | 1997-12-03 | 2000-12-12 | Boehringer Mannheim Gmbh | Chimeric serine proteases |
US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
JP2002510505A (ja) | 1998-04-03 | 2002-04-09 | フィロス インク. | 位置特定可能な蛋白質アレイ |
CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
GB9827228D0 (en) | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
EP2154535A1 (en) | 1998-12-10 | 2010-02-17 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
EP1185559A2 (en) | 1999-04-28 | 2002-03-13 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
CA2377468C (en) | 1999-07-27 | 2010-04-20 | Phylos, Inc. | Peptide acceptor ligation methods |
WO2001072829A2 (en) | 2000-03-31 | 2001-10-04 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
JP2004515219A (ja) | 2000-06-15 | 2004-05-27 | ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 調節可能な触媒活性な核酸 |
CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7598352B2 (en) | 2000-11-17 | 2009-10-06 | University Of Rochester | Method of identifying polypeptide monobodies which bind to target proteins and use thereof |
WO2002081497A2 (en) | 2001-04-04 | 2002-10-17 | University Of Rochester | αξβ3 INTEGRIN-BINDING POLYPEPTIDE MONOBODIES AND THEIR USE |
US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
WO2003022858A2 (de) | 2001-09-11 | 2003-03-20 | Nascacell Gmbh | Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu |
US20080193445A1 (en) | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
EP1575609A4 (en) | 2002-10-23 | 2010-12-15 | Zymogenetics L L C | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29 |
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
US20080220049A1 (en) | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007044688A1 (en) | 2005-10-07 | 2007-04-19 | The Regents Of The University Of California | Nucleic acids encoding modified cytochrome p450 enzymes and methods of use thereof |
EP3811965A1 (en) | 2005-11-23 | 2021-04-28 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
MX2008010633A (es) | 2006-02-24 | 2008-09-25 | Chiesi Farma Spa | Composiciones inmunogenicas anti-amiloides, metodos y usos. |
MX2008013489A (es) | 2006-04-21 | 2008-10-30 | Transgene Sa | Vacuna de virus de papiloma basado en hpv-18 (virus de papiloma humano 18). |
WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
WO2008048970A2 (en) | 2006-10-16 | 2008-04-24 | The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Synthetic antibodies |
AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
JP2010520204A (ja) | 2007-03-02 | 2010-06-10 | アムジェン インコーポレイテッド | 腫瘍疾患を治療するための方法および組成物 |
US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
WO2009023184A2 (en) | 2007-08-10 | 2009-02-19 | Protelix, Inc. | Universal fibronectin type iii binding-domain libraries |
US20100285000A1 (en) | 2007-08-20 | 2010-11-11 | Bristol-Myers Squibb Company | Use of vegfr-2 inhibitors for treating metastatic cancer |
WO2009058379A2 (en) | 2007-10-31 | 2009-05-07 | Medimmune, Llc | Protein scaffolds |
WO2009073115A1 (en) | 2007-11-28 | 2009-06-11 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with mtor inhibitors |
WO2009086116A2 (en) | 2007-12-19 | 2009-07-09 | Centocor, Inc. | Alternative scaffold protein fusions phage display via fusion to plx of m13 phage |
KR20100111283A (ko) | 2007-12-27 | 2010-10-14 | 노파르티스 아게 | 개선된 피브로넥틴계 결합 분자 및 그들의 용도 |
AU2009213151B2 (en) | 2008-02-12 | 2012-07-12 | Certusview Technologies, Llc | Searchable electronic records of underground facility locate marking operations |
MX2010008874A (es) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico. |
EP2274331B1 (en) | 2008-05-02 | 2013-11-06 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
CN102099373A (zh) | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | 基于纤连蛋白的多价支架结构域蛋白 |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
DK2356269T3 (en) | 2008-10-31 | 2016-08-15 | Janssen Biotech Inc | FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
AU2009327189B2 (en) | 2008-12-16 | 2012-09-06 | Novartis Ag | Yeast display systems |
WO2010093771A1 (en) | 2009-02-11 | 2010-08-19 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with temozolomide |
WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
US8067201B2 (en) | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
EP2464663A4 (en) | 2009-08-13 | 2013-05-29 | Massachusetts Inst Technology | RECOMBINANT PROTEINS COMPRISING MUTANT DOMAINS OF FIBRONECTIN |
ES2860453T3 (es) | 2009-10-30 | 2021-10-05 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
EP2533807A2 (en) | 2010-02-12 | 2012-12-19 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
BR112012019881A2 (pt) | 2010-02-18 | 2017-06-27 | Bristol Myers Squibb Co | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 |
US9249508B2 (en) | 2010-03-14 | 2016-02-02 | Mark S. Braiman | Bromine-sensitized solar photolysis of carbon dioxide |
CA2795325A1 (en) | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
KR20130056871A (ko) | 2010-04-13 | 2013-05-30 | 브리스톨-마이어스 스큅 컴퍼니 | Pcsk9에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질 |
RU2603272C2 (ru) | 2010-04-30 | 2016-11-27 | Янссен Байотек, Инк. | Композиции на основе стабилизированных фибронектиновых доменов, способы и области их применения |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
AU2011283646B2 (en) | 2010-07-30 | 2015-07-09 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
JP2014504587A (ja) | 2010-12-22 | 2014-02-24 | ブリストル−マイヤーズ スクイブ カンパニー | Il−23に結合するフィブロネクチンをベースとするスカフォールドドメインタンパク質 |
DK2697257T3 (en) | 2011-04-13 | 2017-01-30 | Bristol Myers Squibb Co | FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS |
US9347058B2 (en) | 2011-05-17 | 2016-05-24 | Bristol-Myers Squibb Company | Methods for the selection of binding proteins |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
US9200273B2 (en) | 2011-09-27 | 2015-12-01 | Janssen Biotech, Inc. | Fibronectin type III repeat based protein scaffolds with alternative binding surfaces |
CN113150117A (zh) | 2014-03-20 | 2021-07-23 | 百时美施贵宝公司 | 新的结合血清白蛋白的纤连蛋白iii型结构域 |
US10766946B2 (en) * | 2015-09-23 | 2020-09-08 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type III domains |
-
2011
- 2011-04-29 TW TW100115218A patent/TW201138808A/zh unknown
- 2011-05-02 US US13/098,851 patent/US8969289B2/en active Active
- 2011-05-03 AU AU2011248273A patent/AU2011248273B2/en not_active Ceased
- 2011-05-03 WO PCT/US2011/034998 patent/WO2011140086A2/en active Application Filing
- 2011-05-03 EA EA201270775A patent/EA029334B1/ru not_active IP Right Cessation
- 2011-05-03 AR ARP110101521A patent/AR081459A1/es unknown
- 2011-05-03 CA CA2798510A patent/CA2798510A1/en not_active Abandoned
- 2011-05-03 UY UY0001033366A patent/UY33366A/es not_active Application Discontinuation
- 2011-05-03 CN CN201180033246.3A patent/CN103003301B/zh not_active Expired - Fee Related
- 2011-05-03 JP JP2013509178A patent/JP5876872B2/ja not_active Expired - Fee Related
- 2011-05-03 PE PE2012002119A patent/PE20130593A1/es not_active Application Discontinuation
- 2011-05-03 SG SG2012080032A patent/SG185091A1/en unknown
- 2011-05-03 CN CN201610756654.6A patent/CN107698682A/zh active Pending
- 2011-05-03 EP EP11730481.6A patent/EP2566888A2/en not_active Withdrawn
- 2011-05-03 BR BR112012028162-3A patent/BR112012028162A2/pt not_active IP Right Cessation
- 2011-05-03 SG SG10201503366XA patent/SG10201503366XA/en unknown
- 2011-05-03 MX MX2015004831A patent/MX346557B/es unknown
- 2011-05-03 MX MX2012012800A patent/MX2012012800A/es active IP Right Grant
- 2011-05-03 KR KR1020127031428A patent/KR101854931B1/ko active IP Right Grant
-
2012
- 2012-10-30 TN TNP2012000518A patent/TN2012000518A1/en unknown
- 2012-10-31 CL CL2012003077A patent/CL2012003077A1/es unknown
- 2012-11-01 CO CO12197670A patent/CO6630173A2/es not_active Application Discontinuation
- 2012-11-01 IL IL222832A patent/IL222832A0/en active IP Right Grant
- 2012-11-30 ZA ZA2012/09091A patent/ZA201209091B/en unknown
-
2014
- 2014-11-25 US US14/552,823 patent/US9540424B2/en active Active
-
2015
- 2015-10-27 JP JP2015210912A patent/JP6219357B2/ja not_active Expired - Fee Related
-
2016
- 2016-11-29 US US15/363,724 patent/US10221438B2/en active Active
-
2017
- 2017-09-27 JP JP2017185708A patent/JP2018057368A/ja active Pending
-
2019
- 2019-01-10 US US16/244,921 patent/US10934572B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6630173A2 (es) | Moléculas de unión a seroalbuminae | |
ECSP13013102A (es) | Dominios no inmunizados que se unen al suero y su uso para extender la vida media en el suero | |
EA202090216A2 (ru) | Связывающие сывороточный альбумин домены фибронектина iii типа | |
DOP2014000083A (es) | Inmunoenlazadores dirigidos contra el tnf | |
EA201892796A1 (ru) | Связывающиеся с сывороточным альбумином домены фибронектина типа iii | |
CO6382161A2 (es) | Moleculas biespecificas de union a egfr/igfir | |
MX353382B (es) | Moleculas de union polipeptido de larga duracion. | |
UY35484A (es) | Molécula de unión de cadena simple que comprenden ABP de extremo N | |
CL2011002129A1 (es) | Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17. | |
UY31123A1 (es) | Proteinas de fusion natriureticas | |
EA201491524A1 (ru) | Связывающиеся с эритроцитами терапевтические средства | |
BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
MX2014005546A (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
CR20150437A (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
WO2017053619A8 (en) | Glypican-3binding fibronectin based scafflold molecules | |
BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
CR20120506A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
EA201490745A1 (ru) | Полипептиды антител, которые вызывают антагонизм cd40l | |
EA201591700A1 (ru) | Гибридные белки апелина и их применение | |
EA201390923A1 (ru) | Модифицированное антитело с улучшенным полупериодом существования | |
CL2013003090A1 (es) | Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso. | |
CL2012002884A1 (es) | Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido. | |
AR080914A1 (es) | Proteinas de union al beta-amiloide | |
MX361076B (es) | Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |